<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323062</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 1030</org_study_id>
    <nct_id>NCT01323062</nct_id>
  </id_info>
  <brief_title>Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects</brief_title>
  <official_title>A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended
      phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects
      with previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with measurable disease will be assessed for response after every 2 cycles of
      therapy using RECIST 1.1 criteria. In addition, progression free survival (PFS), overall
      survival (OS) and exploratory biomarkers, imaging, and thrombotic risk parameters will be
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 4, 2016</completion_date>
  <primary_completion_date type="Actual">May 14, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure number of severe side effects seen during first cycle of therapy</measure>
    <time_frame>Three weeks</time_frame>
    <description>To determine the maximum tolerated dose based on occurrence of dose-limititing toxicity (DLT) within the first 3 weeks of treatment to determine appropriate and safe dose of bavituximab in combination with carboplatin and pemetrexed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At the time from the start of treatment until documented disease as defined bia RECIST 1.1 or death</time_frame>
    <description>to determine the overall response rate and estimate progression free survival associated with bavituximab in combination with carboplatin and pemetrexed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Non Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Single-arm trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-arm trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bavituximab</intervention_name>
    <description>Administered 3 mg/kg weekly</description>
    <arm_group_label>Single-arm trial</arm_group_label>
    <other_name>chimeric 3G4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than or equal to 18

          -  Histologically or cytologically confirmed stage IV non-squamous NSCLC not previously
             treated with systemic chemotherapy

          -  Evaluable disease by clinical or radiographic parameters

          -  No history or concomitant malignancy

          -  Adequate organ and marrow function

          -  Female subjects with negative urine or serum pregnancy

          -  ECOG must be 0 or 1

        Exclusion Criteria:

          -  Squamous cell, small cell, or mixed histology

          -  Known history of bleeding diathesis or coagulopathy

          -  Cavitary tumors or tumors invading or abutting large blood vessels

          -  Any history of thromboembolic events

          -  Ongoing therapy with oral or parenteral anticoagulants

          -  Major surgery within 4 weeks of Day 1 of treatment

          -  Uncontrolled intercurrent disease (diabetes, hypertension, thyroid disease)

          -  any history of significant vascular disease

          -  Congestive heart failure

          -  History of any condition requiring anti-platelet therapy

          -  Serious non healing wound

          -  Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis

          -  Unable or unwilling to discontinue use of prohibited medications

          -  D-dimers &gt;2 x ULN as measured on 2 separate occasions at least 1 day apart
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juneko Grilley Olson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U of North Carolina at Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.unclineberger.org</url>
    <description>web address for Lineberger Comprehensive Cancer Center, UNC</description>
  </link>
  <link>
    <url>http://www.cancer.gov</url>
    <description>web address for the National Cancer Institute (NCI)</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy naive</keyword>
  <keyword>stage IV non squamous non small cell lung cancer</keyword>
  <keyword>Phase 1b</keyword>
  <keyword>Bavituximab</keyword>
  <keyword>Chimeric 3G4</keyword>
  <keyword>U of North Carolina at Chapel Hill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

